Literature DB >> 25697690

Chinese vaccine products go global: vaccine development and quality control.

Miao Xu1, Zhenglun Liang, Yinghua Xu, Junzhi Wang.   

Abstract

Through the continuous efforts of several generations, China has become one of the few countries in the world that is capable of independently addressing all the requirements by the Expanded Program on Immunization. Regulatory science is applied to continuously improve the vaccine regulatory system. Passing the prequalification by WHO has allowed Chinese vaccine products to go global. Chinese vaccine products not only secure disease prevention and control domestically but also serve the needs for international public health. This article describes the history of Chinese vaccine development, the current situation of Chinese vaccine industry and its contribution to the prevention and control of infectious diseases. We also share our experience of national quality control and vaccine regulation during the past decades. China's experience in vaccine development and quality control can benefit other countries and regions worldwide, including the developing countries.

Entities:  

Keywords:  China; WHO prequalification; infectious diseases; quality control; regulatory science; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25697690     DOI: 10.1586/14760584.2015.1012503

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  9 in total

Review 1.  Human leptospirosis vaccines in China.

Authors:  Yinghua Xu; Qiang Ye
Journal:  Hum Vaccin Immunother       Date:  2017-12-19       Impact factor: 3.452

Review 2.  Hepatitis E virus: Current epidemiology and vaccine.

Authors:  Xing Wu; Pan Chen; Huijuan Lin; Xiaotian Hao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

3.  Profit considerations in vaccine safety-related events in China.

Authors:  Jianlin Zhuang; Yihan Lu; Abram L Wagner; Qingwu Jiang
Journal:  Expert Rev Vaccines       Date:  2019-11-13       Impact factor: 5.217

4.  Procurement of Category 2 Vaccines in China.

Authors:  Jian-Lin Zhuang; Abram L Wagner; Megan Laffoon; Yi-Han Lu; Qing-Wu Jiang
Journal:  Vaccines (Basel)       Date:  2019-08-23

Review 5.  Vaccine Prices: A Systematic Review of Literature.

Authors:  Rabia Hussain; Nadeem Irfan Bukhari; Anees Ur Rehman; Mohamed Azmi Hassali; Zaheer-Ud-Din Babar
Journal:  Vaccines (Basel)       Date:  2020-10-29

6.  The development of China's vaccine industry in the past decade: the perspective from drug regulatory science.

Authors:  Guanjie Wang; Mingli Shao
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

7.  Meningococcal vaccines in China.

Authors:  Yinghua Xu; Yanan Li; Shanshan Wang; Maoguang Li; Miao Xu; Qiang Ye
Journal:  Hum Vaccin Immunother       Date:  2021-02-10       Impact factor: 3.452

8.  A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China.

Authors:  Yangmu Huang; Ke Pan; Danlu Peng; Andy Stergachis
Journal:  Malar J       Date:  2018-04-03       Impact factor: 2.979

9.  The landscape of vaccines in China: history, classification, supply, and price.

Authors:  Yaming Zheng; Lance Rodewald; Juan Yang; Ying Qin; Mingfan Pang; Luzhao Feng; Hongjie Yu
Journal:  BMC Infect Dis       Date:  2018-10-04       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.